Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
The Journal of Investigative Dermatology
|
December 20, 2021
The Role for miR-146b-5p in the Attenuation of Dermal Fibrosis and Angiogenesis by Targeting PDGFRα in Skin Wounds
Chie Fujisawa, Makoto Hamanoue, Yayoi Kawano, et al.
Journal of Neurosurgery
|
May 6, 2017
High programmed cell death 1 ligand-1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma
Daiki Murata, Yohei Mineharu, Yoshiki Arakawa, et al.
Plos One
|
April 5, 2018
PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes
Bin Liu, Yoshiki Arakawa, Ryuta Yokogawa, et al.
Cancer Treatment and Research Communications
|
February 13, 2026
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer
Koichi Azuma, Mitsuo Osuga, Shoichi Itoh, et al.
Current Urology
|
September 11, 2023
Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma
Jun Teishima, Daiki Murata, Kazuma Yukihiro, et al.
Pathology, Research and Practice
|
June 21, 2015
High mobility group A1 expression shows negative correlation with recurrence time in patients with glioblastoma multiforme
Bin Liu, Bo Pang, Huajie Liu, et al.
Anticancer Research
|
October 1, 2021
CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma
Yohei Sekino, Kenshiro Takemoto, Daiki Murata, et al.
Anticancer Research
|
September 3, 2021
P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma
Yohei Sekino, Kenshiro Takemoto, Daiki Murata, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 31, 2025
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients
Tae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Anticancer Research
|
October 28, 2025
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
Aosa Sasada, Hayato Kawachi, Tadaaki Yamada, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
The Journal of Investigative Dermatology
|
December 20, 2021
The Role for miR-146b-5p in the Attenuation of Dermal Fibrosis and Angiogenesis by Targeting PDGFRα in Skin Wounds
Chie Fujisawa, Makoto Hamanoue, Yayoi Kawano, et al.
Journal of Neurosurgery
|
May 6, 2017
High programmed cell death 1 ligand-1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma
Daiki Murata, Yohei Mineharu, Yoshiki Arakawa, et al.
Plos One
|
April 5, 2018
PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes
Bin Liu, Yoshiki Arakawa, Ryuta Yokogawa, et al.
Cancer Treatment and Research Communications
|
February 13, 2026
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer
Koichi Azuma, Mitsuo Osuga, Shoichi Itoh, et al.
Current Urology
|
September 11, 2023
Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma
Jun Teishima, Daiki Murata, Kazuma Yukihiro, et al.
Pathology, Research and Practice
|
June 21, 2015
High mobility group A1 expression shows negative correlation with recurrence time in patients with glioblastoma multiforme
Bin Liu, Bo Pang, Huajie Liu, et al.
Anticancer Research
|
October 1, 2021
CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma
Yohei Sekino, Kenshiro Takemoto, Daiki Murata, et al.
Anticancer Research
|
September 3, 2021
P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma
Yohei Sekino, Kenshiro Takemoto, Daiki Murata, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 31, 2025
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients
Tae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Anticancer Research
|
October 28, 2025
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
Aosa Sasada, Hayato Kawachi, Tadaaki Yamada, et al.
Page
of 8